Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO Adds Jaw Osteonecrosis Recommendations to Bisphosphonate Guideline

Executive Summary

The American Society of Clinical Oncology's updated guideline for the use of bisphosphonates in patients with multiple myeloma warns of osteonecrosis of the jaw as a potential adverse effect, and agrees with the recommendations in revised FDA labels for the bone-strengthening drugs

You may also be interested in...



Boniva Labeling Reflects Class Osteonecrosis, Musculoskeletal Pain Risk

Labeling for Roche/GlaxoSmithKline's once-monthly osteoporosis agent Boniva reflects upcoming class labeling for osteonecrosis and musculoskeletal pain risk with oral bisphosphonates

Zometa, Aredia May Have Different Jaw Osteonecrosis Risk Profiles

Further study of jaw osteonecrosis risk may differentiate Novartis' bisphosphonates Zometa and Aredia, FDA Division of Oncology Drug Products Director Richard Pazdur suggested

IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns

The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.

UsernamePublicRestriction

Register

PS048415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel